Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26417680 | 0.83 | ELANE (0.46) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1743550 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4ERAB9AELANEKMT2A | |
| SCHEMBL1663454 | 0.81 | SMN1; SMN2 (0.48) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL91073 | 0.78 | GAA (0.53) | ALDH1A1NPC1RAB9AHSD17B10LMNA | |
| SCHEMBL9619687 | 0.77 | ELANE (0.53) | ALDH1A1KDM4EELANEKMT2AMEN1 | |
| SCHEMBL13883703 | 0.77 | KMT2A (0.54) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL13936274 | 0.77 | GAA (0.49) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL17355713 | 0.76 | ELANE (0.51) | NPC1RAB9AELANEKMT2A | |
| SCHEMBL3657487 | 0.76 | ACHE (0.54) | ALDH1A1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL17845269 | 0.76 | MAPT (0.55) | ALDH1A1KDM4EHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387440-B1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2016-11-09 | — | — | EP | disclosed |
| EP-2387440-B1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2016-11-09 | — | — | EP | disclosed |
| US-20130060029-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | CHEN WEICHUN (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060029-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | CHEN WEICHUN (US) | 2013-03-07 | — | — | US | disclosed |
| US-8349852-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-8349852-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-8349852-B2 | Quinazolinone derivatives useful as vanilloid antagonists | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| EP-2387440-A2 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2011-11-23 | — | — | EP | disclosed |
| US-20110254530-A1 | FAULT PROTECTED CURRENT SOURCE FOR LIGHTING ELEMENT TESTING | VEKTREX ELECTRONIC SYSTEMS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20100197705-A1 | Quinazolinone Derivatives Useful as Vanilloid Antagonists | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-08-05 | — | — | US | disclosed |
| US-20100197705-A1 | Quinazolinone Derivatives Useful as Vanilloid Antagonists | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-08-05 | — | — | US | disclosed |
| US-20100197705-A1 | Quinazolinone Derivatives Useful as Vanilloid Antagonists | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-08-05 | — | — | US | disclosed |
| WO-2010084050-A2 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010084050-A2 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197705-A1 | Quinazolinone Derivatives Useful as Vanilloid Antagonists | KCNA4, KCNA3, KCNB1 | ALDH1A1 1332/4885KDM4E 1546/4885NPC1 2787/4885 |
| US-20130060029-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | TRPV1, KCNJ2, TRPV3 | ALDH1A1 876/4885KDM4E 1597/4885NPC1 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.